Incyte secured European Commission approval for its once-daily oral therapy Povofortay to treat adults with moderate-to-severe hidradenitis suppurativa. The endorsement expands the drugmaker's immunology portfolio beyond its flagship blood cancer treatment Jakafi. The approval provides a new revenue driver as competition intensifies against established therapies.

Clinical Data and Market Positioning